केन्या - अंग्रेज़ी - Pharmacy and Poisons Board

cipla limited cipla house, peninsula business park, ganpatrao - empagliflozin & metformin hydrochloride usp - tablet - each extended release tablet contains:… - metformin and empagliflozin

केन्या - अंग्रेज़ी - Pharmacy and Poisons Board

cipla limited cipla house, peninsula business park, ganpatrao - empagliflozin & metformin hydrochloride usp - tablet - each extended release tablet contains:… - metformin and empagliflozin

सिंगापुर - अंग्रेज़ी - HSA (Health Sciences Authority)

boehringer ingelheim singapore pte. ltd. - empagliflozin; linagliptin - tablet, film coated - empagliflozin 10.00 mg; linagliptin 5.00 mg

सिंगापुर - अंग्रेज़ी - HSA (Health Sciences Authority)

boehringer ingelheim singapore pte. ltd. - empagliflozin; linagliptin - tablet, film coated - empagliflozin 25.00 mg; linagliptin 5.00 mg

न्यूज़ीलैंड - अंग्रेज़ी - Medsafe (Medicines Safety Authority)

boehringer ingelheim (nz) limited - empagliflozin 12.5mg;  ; metformin hydrochloride 1000mg;   - film coated tablet - 12.5mg/1000mg - active: empagliflozin 12.5mg   metformin hydrochloride 1000mg   excipient: colloidal silicon dioxide copovidone magnesium stearate maize starch opadry purple 02b200006 - glycaemic control jardiamet is indicated as an adjunct to diet and exercise to improve glycaemic control in adult patients with type 2 diabetes mellitus: · when treatment with both empagliflozin and metformin is appropriate ·inadequately controlled with metformin or empagliflozin alone ·inadequately controlled with empagliflozin or metformin in combination with other glucose-lowering products including insulin · already treated with empagliflozin and metformin co-administered as separate tablets.

न्यूज़ीलैंड - अंग्रेज़ी - Medsafe (Medicines Safety Authority)

boehringer ingelheim (nz) limited - empagliflozin 12.5mg;  ; metformin hydrochloride 500mg;   - film coated tablet - 12.5mg/500mg - active: empagliflozin 12.5mg   metformin hydrochloride 500mg   excipient: colloidal silicon dioxide copovidone magnesium stearate maize starch opadry pink 02b20004 - glycaemic control jardiamet is indicated as an adjunct to diet and exercise to improve glycaemic control in adult patients with type 2 diabetes mellitus: · when treatment with both empagliflozin and metformin is appropriate ·inadequately controlled with metformin or empagliflozin alone ·inadequately controlled with empagliflozin or metformin in combination with other glucose-lowering products including insulin · already treated with empagliflozin and metformin co-administered as separate tablets.

न्यूज़ीलैंड - अंग्रेज़ी - Medsafe (Medicines Safety Authority)

boehringer ingelheim (nz) limited - empagliflozin 12.5mg;  ; metformin hydrochloride 850mg;   - film coated tablet - 12.5mg/850mg - active: empagliflozin 12.5mg   metformin hydrochloride 850mg   excipient: colloidal silicon dioxide copovidone magnesium stearate maize starch opadry pink 02b240006 - glycaemic control jardiamet is indicated as an adjunct to diet and exercise to improve glycaemic control in adult patients with type 2 diabetes mellitus: · when treatment with both empagliflozin and metformin is appropriate ·inadequately controlled with metformin or empagliflozin alone ·inadequately controlled with empagliflozin or metformin in combination with other glucose-lowering products including insulin · already treated with empagliflozin and metformin co-administered as separate tablets.

न्यूज़ीलैंड - अंग्रेज़ी - Medsafe (Medicines Safety Authority)

boehringer ingelheim (nz) limited - empagliflozin 5mg;  ; metformin hydrochloride 1000mg;   - film coated tablet - 5mg/1000mg - active: empagliflozin 5mg   metformin hydrochloride 1000mg   excipient: colloidal silicon dioxide copovidone magnesium stearate maize starch opadry yellow 02b220012 - glycaemic control jardiamet is indicated as an adjunct to diet and exercise to improve glycaemic control in adult patients with type 2 diabetes mellitus: · when treatment with both empagliflozin and metformin is appropriate ·inadequately controlled with metformin or empagliflozin alone ·inadequately controlled with empagliflozin or metformin in combination with other glucose-lowering products including insulin · already treated with empagliflozin and metformin co-administered as separate tablets.

न्यूज़ीलैंड - अंग्रेज़ी - Medsafe (Medicines Safety Authority)

boehringer ingelheim (nz) limited - empagliflozin 5mg;  ; metformin hydrochloride 500mg;   - film coated tablet - 5mg/500mg - active: empagliflozin 5mg   metformin hydrochloride 500mg   excipient: colloidal silicon dioxide copovidone magnesium stearate maize starch opadry yellow 02b220011 - glycaemic control jardiamet is indicated as an adjunct to diet and exercise to improve glycaemic control in adult patients with type 2 diabetes mellitus: · when treatment with both empagliflozin and metformin is appropriate ·inadequately controlled with metformin or empagliflozin alone ·inadequately controlled with empagliflozin or metformin in combination with other glucose-lowering products including insulin · already treated with empagliflozin and metformin co-administered as separate tablets.

न्यूज़ीलैंड - अंग्रेज़ी - Medsafe (Medicines Safety Authority)

boehringer ingelheim (nz) limited - empagliflozin 5mg;  ; metformin hydrochloride 850mg;   - film coated tablet - 5mg/850mg - active: empagliflozin 5mg   metformin hydrochloride 850mg   excipient: colloidal silicon dioxide copovidone magnesium stearate maize starch opadry yellow 02b220010 - glycaemic control jardiamet is indicated as an adjunct to diet and exercise to improve glycaemic control in adult patients with type 2 diabetes mellitus: · when treatment with both empagliflozin and metformin is appropriate ·inadequately controlled with metformin or empagliflozin alone ·inadequately controlled with empagliflozin or metformin in combination with other glucose-lowering products including insulin · already treated with empagliflozin and metformin co-administered as separate tablets.